AADI - Aadi Bioscience, Inc.
2.79
-0.070 -2.509%
Share volume: 109,912
Last Updated: Fri 21 Feb 2025 10:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.34%
PREVIOUS CLOSE
CHG
CHG%
$2.86
-0.07
-0.02%
Fundamental analysis
36%
Profitability
35%
Dept financing
23%
Liquidity
75%
Performance
30%
Performance
5 Days
3.33%
1 Month
-6.69%
3 Months
21.30%
6 Months
80.00%
1 Year
47.62%
2 Year
-75.48%
Key data
Stock price
$2.79
DAY RANGE
$2.78 - $2.88
52 WEEK RANGE
$1.21 - $3.81
52 WEEK CHANGE
$40.91
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Neil P. Desai
Region: US
Website: aadibio.com
Employees: 40
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: aadibio.com
Employees: 40
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin.
Recent news